Balchem Corporation 2010 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2010. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, nutritional, feed, pharmaceutical, and medical sterilization industries. The company operates through three reportable segments: Specialty Products (medical sterilization gases and fumigants), Food, Pharma & Nutrition (microencapsulation solutions and choline nutrients), and Animal Nutrition & Health (choline chloride, chelated minerals, and specialty feed ingredients).
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Net Sales | $255.1 million | $219.4 million |
| Gross Margin | $78.0 million (30.6%) | $67.0 million (30.5%) |
| Operating Income | $49.8 million (19.5%) | $40.7 million (18.5%) |
| Net Earnings | $33.3 million | $26.8 million |
| Diluted EPS | $1.12 | $0.93 |
| Cash & Equivalents | $77.3 million | $46.4 million |
| Total Debt | $4.9 million | $6.8 million |
| Working Capital | $100.1 million | $59.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16.2% to $255.1 million, driven by volume growth across all segments. The Animal Nutrition & Health segment contributed the largest absolute increase ($23.2 million), while the Food, Pharma & Nutrition segment saw an 18.6% increase.
- Profitability: Net earnings rose 24.2% to $33.3 million. Operating margins improved to 19.5% from 18.5%, despite higher petrochemical-based raw material costs.
- Acquisition: In June 2010, the company acquired Aberco, Inc., a marketer of propylene oxide, contributing to sales growth in the Specialty Products segment.
- Liquidity: Cash and cash equivalents increased significantly by $30.8 million, primarily due to strong operating cash flows ($39.0 million) and reduced debt levels.
- Capital Expenditures: Increased to $7.6 million in 2010 from $3.4 million in 2009, reflecting investments in production capacity.
Outlook, Risks, and Management Commentary
- Guidance: Capital expenditures for 2011 are projected to range between $8.0 million and $9.0 million. The company expects to continue generating sufficient cash flow to fund operations and potential acquisitions.
- Operational Changes: The company plans to terminate its lease and cease operations at its Channahon, Illinois facility effective June 30, 2011.
- Risks:
- Regulatory: Operations depend on EPA registrations for ethylene oxide and propylene oxide. While currently approved, future re-examinations could impact the business.
- Raw Materials: Prices for petrochemicals, minerals, and metals fluctuate and may not be fully passable to customers.
- Macroeconomic: Global economic conditions and credit availability for customers could impact sales and collections.
- Environmental: The Verona, Missouri facility is a designated Superfund site; however, the company is indemnified by the prior owner for remediation liabilities.
- Unusual Items: Included a non-recurring net gain of approximately $73,000 related to the sale of a non-core calcium carbonate product line.
Investor Verification Checklist
- Verify the status of EPA re-registration for ethylene oxide and propylene oxide products.
- Monitor raw material cost trends (petrochemicals) and their impact on gross margins.
- Assess the integration and performance contribution of the Aberco, Inc. acquisition.
- Review the timeline and financial impact of closing the Channahon, Illinois facility.
- Confirm compliance with debt covenants (Current Ratio, Funded Debt Ratio, Fixed Charge Coverage Ratio).